Abstract 3695
Background
FOLFOX (5-flourouracil, leucovorin, oxaliplatin) and FOLFIRI (fluorouracil, leucovorin, irinotecan) in combination with targeted agents are standard-of-care options for patients for mCRC with response rates >50% in first line. In the second line setting, efficacy of chemotherapy and targeted agents are much lower with response rates of 4% for FOLFIRI + bevacizumab (Tabernero 2014) and treatment options are limited in particular for the 50 % of patients harboring a RAS mutation. Polo-like kinase 1 (PLK1) is a serine/threonine kinase, master regulator of G2/M cell-cycle progression and genome wide RNAi screens identified PLK1 to be synthetic lethal for KRAS mutated tumor cells inducing arrest and apoptosis (Luo 2009). Onvansertib is an oral, highly selective PLK1 inhibitor that demonstrates single agent and synergistic activity with irinotecan in preclinical CRC models. Additionally, KRAS mutated vs wild-type tumor cells showed higher sensitivity to onvansertib. PLK1 inhibition is a potential target in KRAS-mutated mCRC and onvansertib + FOLFIRI may provide a new second-line treatment option.
Trial design
The primary objective of this single-arm study is to assess the safety and preliminary efficacy of onvansertib in combination with FOLFIRI and bevacizumab in the second line setting for KRAS-mutated mCRC patients by determining the MTD and RP2D in the Phase 1b segment of the trial, and using the RP2D to treat patients in the Phase 2 continuation segment. For the phase 1b, a standard 3 + 3 dose-escalation design will be used with enrollment stopping when 6 patients have been treated at the highest dose level at which 1 or fewer patients experience a DLT. For the phase 2, based on a one-sided one sample log-rank test with 10% Type I error, there will be at least 90% power to detect an improvement in ORR from 5% to 20% with 26 patients. Preliminary efficacy will be determined by objective response (RECIST v1.1) and exploratory studies include quantitation of KRAS circulating tumor DNA (ctDNA) and genomic studies of circulating tumor cells and ctDNA to determine activated pathways that correlate with patient response.
Clinical trial identification
NCT03829410.
Editorial acknowledgement
Legal entity responsible for the study
Trovagene.
Funding
Trovagene.
Disclosure
M. Erlander: Full / Part-time employment: Trovagene. All other authors have declared no conflicts of interest.
Resources from the same session
1571 - Thyroid Lobectomy versus Total Thyroidectomy among Early-Stage Papillary Thyroid Carcinoma Patient
Presenter: Sara Ahmed
Session: Poster Display session 2
Resources:
Abstract
5051 - Classification of thyroid nodule using DNA methylation profiling on tissue and circulating tumor DNA
Presenter: Shubin Hong
Session: Poster Display session 2
Resources:
Abstract
4155 - Durvalumab plus Tremelimumab for the Treatment of Patients (pts) with Refractory and Progressive Advanced Thyroid Carcinoma. A Phase II Multicohort Trial (DUTHY / GETNE T1812)
Presenter: Jorge Hernando Cubero
Session: Poster Display session 2
Resources:
Abstract